Exhibit 10.2

 

***Text Omitted and Filed Separately

With Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Section 200.80(b)(4)

and 240.24b-2

 

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE  PAGE OF
PAGES   1       23   2.  AMENDMENT/MODIFICATION NO.  3.  EFFECTIVE DATE
  4.  REQUISITION/PURCHASE REQ. NO.  5.  PROJECT NO. (if applicable)   0019 See
Block 16C OS139427     6.  ISSUED BY CODE ASPR-BARDA

7. ADMINISTERED BY (If other than Item 6)

 

CODE ASPR-BARDA02  

ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201

 

ASPR-BARDA

330 Independence Ave, SW, Rm G640

Washington DC 20201

 

  8.  NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
(x)  9A.  AMENDMENT OF SOLICITATION NO.  

 

CHIMERIX, INC. 1377270

CHIMERIX, INC. 2505 MERIDIAN P

2505 MERIDIAN PKWY STE 340

DURHAM NC 277135246

       9B.  DATED (SEE ITEM 11)         x

10A. MODIFICATION OF CONTRACT/ORDER NO.

HHSO100201100013C

       

10B. DATED (SEE ITEM 13)

02/16/2011

 

CODE

1377270

FACILITY CODE     11.  THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  

o The above numbered solicitation is amended as set forth in Item 14. The hour
and date specified for receipt of Offers            o is extended.    o is not
extended Offers must acknowledge receipt of this amendment prior to the hour and
date specified in the solicitation or as amended, by one of the following
methods: (a) By completing Items 8 and 15, and returning ___________ copies of
the amendment; (b) By acknowledging receipt of this amendment on each copy of
the offer submitted; or (c) By separate letter or telegram which includes a
reference to the solicitation and amendment numbers. FAILURE OF YOUR
ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS
PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If
by virtue of this amendment you desire to change an offer already submitted,
such change may be made by telegram or letter, provided each telegram or letter
makes reference to the solicitation and this amendment, and is received prior to
the opening hour and date specified.

 

12. ACCOUNTING AND APPROPRIATION DATA (if required)
                                       Net Increase:
                                          $16,951,226.00

..2014.1992003.25106

  13.  THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES
THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.   CHECK ONE A.  THIS CHANGE
ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM
14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.         B.  THE ABOVE
NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such
as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14,
PURSUANT TO THE AUTHORITY OF FAR 43.103(b).     C.  THIS SUPPLEMENTAL AGREEMENT
IS ENTERED INTO PURSUANT TO AUTHORITY OF:   x

D.  OTHER (Specify type of modification and authority)

Bilateral:       Mutual Agreement of the Parties and FAR Clause 52.217-9.

  E.  IMPORTANT:              Contractor                         o  is not.
            x  is required to sign this document and return         0       
copies to the issuing office.   14.  DESCRIPTION OF AMENDMENT/MODIFICATION
(Organized by UCF section headings, including solicitation/contract subject
matter where feasible.)  

Tax ID Number:             33-0903395

DUNS Number:      121785997

A.             The purpose of this modification is for the Government to both
bilaterally re-establish and exercise Option 2/CLIN 0003 of the contract in
accordance with the terms and conditions of both Option 2/CLIN 0003 and the
contract. The Government and the Contractor hereby bilaterally modify this
contract for the purposes of both re-establishing and exercising
the total amount of Option 2/CLIN 0003 in the amount of:

 

Total Estimated Cost: $[…***…]

Total Fixed Fee: $[…***…]

Total Estimated Cost Plus Fixed Fee: $16,951,226.00

Continued ...

  Except as provided herein, all terms and conditions of the document referenced
in Item 9A or 10A, as heretofore changed, remains unchanged and in full force
and effect.   15A.  NAME AND TITLE OF SIGNER (Type or print)  16A.  NAME AND
TITLE OF CONTRACTING OFFICER (Type or print)   Michael Rogers, Chief Development
Officer ETHAN J. MUELLER   15B.  CONTRACTOR/OFFEROR  15C.  DATE SIGNED

16B. UNITED STATES OF AMERICA

 

 16C.  DATE SIGNED   /s/ Michael Rogers ______________________  
___________________________________________    

(Signature of person authorized to sign)

8/27/14

(Signature of Contracting Officer)

                                 

NSN 7540-01-152-8070 STANDARD FORM 30 (REV. 10-83) Previous edition unusable
Prescribed by GSA   FAR (48 CFR) 53.243

 

***Confidential Treatment Requested

 

 

 

 

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201100013C/0019

PAGE OF 2        23

NAME OF OFFEROR OR CONTACTOR

CHIMERIX, INC. 1377270

ITEM NO.

(A)

SUPPLIES/SERVICES

(B)

QUANTITY

(C)

UNIT

(D)

UNIT PRICE

(E)

AMOUNT

(F)

 

 

The total period of performance of Option 2/CLIN 0003 under the contract is from
1 September 2014 through 30 November 2015.

 

1.  This modification hereby results in an increase in the total amount of the
contract from $36,262,373.00 by $16,951,226.00 to $53,213,599.00 as well as the
following:

 

Total Estimated Cost of the Contract: From $[…***…] By $[…***…] To $[…***…].

 

Total Fixed Fee of the Contract: From $[…***…] By $[…***…] To $[…***…].

 

Total Estimated Cost Plus Fixed Fee of the Contract: From $36,262,373.00 By
$16,951,226.00 To $53,213,599.00.

 

2.  Block 15G of the SF 26, the amount of $36,262,373.00 shall be changed to
$53,213,599.00.  In Block 14 of the SF 26, the following CAN Number is added:

 

Appropriation Year: 2014, Object Class: 25106, CAN# 1992003 $16,951,226.00

 

3.  As a result, Attachment 1, Statement of Work dated 23 May 2013, under PART
III, LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS, SECTION J - LIST OF
ATTACHMENTS is hereby deleted and replaced with the attached Statement of Work
dated 31 July 2014.  The efforts within Option 2/CLIN 0003 that involve […***…]
and […***…] cannot be performed until the receipt and approval of all required
Protocols by BARDA inclusive of all IRB, OHRP approvals and any required Ethics
Approvals for any clinical trials/studies and any required approved OLAW
Assurances and IIA approvals from OLAW for any non clinical animal studies.

 

4.  The incorporation of the attached Statement of Work (SOW) changes in the
paragraph above also result in the incorporation of the attached changes into
the contract into WBS Milestones/Deliverables and Technical Deliverables and
Contract Milestones and Go/No Go Decision Gates dated 31 July 2014 under Article
F.2. Deliverables.

 

5.  Total expenses for all domestic and foreign travel (transportation, lodging,
subsistence, and incidental expenses) incurred in direct performance of this
contract shall not exceed $[…***…] during the base segment/CLIN 0001, $[…***…]
during Option Period 1/CLIN 0002 and $ […***…] during Option Period 2/CLIN 0003
without the prior written approval of the Contracting Officer.

 

6.  The first and second sentences in Article G.7. INDIRECT COST RATES of the
contract are replaced with the following:

 

The following rates will be utilized for billing purposes during both the base
period/CLIN 0001, Option 1/CLIN 0002 and Option 2/CLIN 0003 ONLY.

 

Continued ...  

 

 

 

 

 

                         

NSN 7540-01-152-8067 OPTIONAL FORM 336 (4-86)   Sponsored by GSA   FAR (48 CFR)
53.110

 

***Confidential Treatment Requested

 

 

 

 

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201100013C/0019

PAGE OF 3 23

NAME OF OFFEROR OR CONTACTOR

CHIMERIX, INC. 1377270

ITEM NO.

(A)

SUPPLIES/SERVICES

(B)

QUANTITY

(C)

UNIT

(D)

UNIT PRICE

(E)

AMOUNT

(F)

 

 

FY 11 (Retroactive Adjustment base period/CLIN 0001 ONLY) - Fringe Benefits at
[…***…]% and Indirect at […***…]%.

 

FY 12 and FY 13 (Retroactive Adjustment and Billing, base period/CLIN 0001 ONLY
and Billing, Option 1/CLIN 0002 and Option 2/CLIN 0003 ONLY) - Fringe Benefits
at […***…]% and Indirect at […***…]%.

 

7.  The total amount and scope of all other CLINs that are currently being
performed under the contract remain unchanged. This modification does not
exercise any unexercised Option CLINs under the contract and does not authorize
any performance of efforts under any unexercised Option CLINs under the
contract.  In addition, the total amount, scope and period of performance of all
unexercised Option CLINs under the contract remain unchanged. This modification
also confirms that all activities under the base period of performance CLIN 0001
were completed as of 31 May 2013.  The period of performance for Option 1/CLIN
0002 of Contract Number HHSO100201100013C ONLY is hereby changed from 1 June
2013 through 31 August 2014 to 1 June 2013 through 31 October 2014, at no
additional cost to the Government.  The total amount and scope of Option 1/CLIN
0002 of Contract Number HHSO100201100013C remains unchanged.

 

8.  The following clause is hereby added to Article I.1, Section I Contract
Clauses of the contract:

 

HHSAR 352.231-70 Salary Rate Limitation (Aug 2012)

 

B.  This is a bilateral modification.  All other terms and conditions contract
number HHSO100201100013C remain unchanged.

 

Delivery: 11/30/2015

Delivery Location Code:   HHS

HHS

200 Independence Avenue, SW

Washington DC 20201 US

 

Appr. Yr.: 2014 CAN: 1992003 Object Class: 25106

FOB: Destination

Period of Performance: 02/16/2011 to 11/30/2015

 

Change Item 3 to read as follows(amount shown is the obligated amount):

 

[…***…]

 

Reports and Other Data Deliverables.

 

 

 

 

 

     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

16,951,226.00

                 

NSN 7540-01-152-8067 OPTIONAL FORM 336 (4-86)   Sponsored by GSA   FAR (48 CFR)
53.110

 

***Confidential Treatment Requested

 

 

 

 

BARDA Broad Agency Announcement (BAA)

(CBRN-BAA-10-100-SOL-00012)

Advanced Research and Development of Chemical, Biological, Radiological, and

Nuclear Medical Countermeasures

DEVELOPMENT OF CMX-001 FOR THE TREATMENT OF SMALLPOX

Topical Area of Interest No. 3, Antimicrobial Drugs

 

Contractual Statement of Work

 

1.PREAMBLE

 

Independently and not as an agency of the Government, the Contractor shall be
required to furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government, as needed
to perform the Statement of Work submitted in response to the BARDA Broad Agency
Announcement (BAA) CBRN-BAA-10-100-SOL-00012.

 

In accordance with FAR 52.243-2, Changes-Cost Reimbursement (Alt. V), the
Government reserves the right to modify the milestones, progress, schedule,
budget, or to add or delete deliverables, process, or schedules if the need
arises. Because of the nature of this research and development (R&D) contract
and the complexities inherent in this and prior programs, at designated
milestones the Government will evaluate whether work should be redirected,
removed, or whether schedule or budget adjustments should be made.

 

1.0Overall Objectives and Scope

 

The overall objective of this contract is to advance the development of CMX-001
as a broad-spectrum therapeutic antiviral for the treatment of smallpox
infections and dsDNA viruses. The scope of work for this contract includes
preclinical, clinical and manufacturing development activities that fall into
the following areas: non-clinical efficacy studies; clinical activities;
manufacturing activities; and all associated regulatory, quality assurance,
management, and administrative activities. The Research and Development (R&D)
effort for the antiviral will progress in specific stages that cover the base
performance segment and four (4) option segments as specified in this contract.
The Contractor must complete specific tasks required in each of the five
discrete work segments. The scope of work has been broken into the following
five phases which are discrete work segments:

I.[…***…]

II.[…***…]

III.[…***…]

IV.[…***…]

V.[…***…]

 

***Confidential Treatment Requested

 

1

 

 

2.PHASE I: […***…]

Research and development of CMX-001 for the treatment of smallpox and dsDNA
viruses to include the following activities: […***…]. The contractor shall carry
out the following tasks and subtasks and in accordance with an agreed upon
Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and
2.1.9 below) which shall further detail the conduct of the specific tasks and
subtasks.

 

2.1Program Management

 

The Contractor shall provide for the following as outlined below and in the
contract deliverables list (Article F.2):

 

2.1.1The overall management, integration and coordination of all contract
activities, including a technical and administrative infrastructure to ensure
the efficient planning, initiation, implementation, and direction of all
contract activities;

 

2.1.2A Principal Investigator (PI) responsible for project management,
communication, tracking, monitoring and reporting on status and progress, and
modification to the project requirements and timelines, including projects
undertaken by subcontractors; The contract deliverables list (reference),
identifies all contract deliverables and reporting requirements for this
contract.

 

2.1.3Project Manager(s) with responsibility for monitoring and tracking
day-to-day progress and timelines, coordinating communication and project
activities; costs incurred; and program management; The contract deliverables
list (reference), identifies all contract deliverables and reporting
requirements for this contract.

 

2.1.4A BARDA Liaison with responsibility for effective communication with the
Project Officer and Contracting Officer.

 

2.1.5Administrative and legal staff to provide development of compliant
subcontracts, consulting, and other legal agreements, and ensure timely
acquisition of all proprietary rights, including IP rights, and reporting all
inventions made in the performance of the project.

 

2.1.6Administrative staff with responsibility for financial management and
reporting on all activities conducted by the Contractor and any subcontractors.

 

***Confidential Treatment Requested

 

2

 

 

2.1.7Contract Review Meetings.

2.1.7.1The Contractor shall participate in regular meetings to coordinate and
oversee the contract effort as directed by the Contracting and Project Officers.
Such meetings may include, but are not limited to, meeting of the Contractors
and subcontractors to discuss clinical manufacturing progress, product
development, product assay development, scale up manufacturing development,
clinical sample assays development, preclinical/clinical study designs and
regulatory issues; meetings with individual contractors and other HHS officials
to discuss the technical, regulatory, and ethical aspects of the program; and
meeting with technical consultants to discuss technical data provided by the
Contractor.

2.1.7.2The Contractor shall participate in teleconferences every two weeks
between the Contractor and subcontractors and BARDA to review technical
progress. Teleconferences or additional face-to-face meetings shall be more
frequent at the request of BARDA.

2.1.8Integrated Master Schedule

2.1.8.1Within 30 calendar days of the effective date of the contract, the
Contractor shall submit a first draft of an updated Integrated Master Schedule
in a format agreed upon by BARDA to the Project Officer and the Contracting
Officer for review and comment. The Integrated Master Schedule shall be
incorporated into the contract, and will be used to monitor performance of the
contract. Contractor shall include the key milestones and Go/No Go decision
gates. The IMS for the period of performance will be mutually agreed upon at the
PMBR

2.1.9Integrated Master Plan

2.1.9.1Work Breakdown Structure: The Contractor shall utilize a WBS template
agreed upon by BARDA for reporting on the contact. The Contractor shall expand
and delineate the Contract Work Breakdown Structure (CWBS) to a level agreed
upon by BARDA as part of their Integrated Master Plan for contract reporting.
The CWBS shall be discernable and consistent. BARDA may require Contractor to
furnish WBS data at the work package level or at a lower level if there is
significant complexity and risk associated with the task.

2.1.9.2GO/NO-GO Decision Gates: The Integrated Master Plan outlines key
milestones with “Go/No Go” decision criteria (entrance and exit criteria for
each phase of the project). The project plan should include, but not be limited
to, milestones in manufacturing, non-clinical and clinical studies, and
regulatory submissions.

2.1.9.3Earned Value Management System Plan: Subject to the requirements under
HHSAR Clause 352.234-4, the Contractor shall use principles of Earned Value
Management System (EVMS) in the management of this contract. The Seven
Principles are:

I.Plan all work scope for the program to completion.

 

3

 

 

II.Break down the program work scope into finite pieces that can be assigned to
a responsible person or organization for control of technical, schedule, and
cost objectives.

III.Integrate program work scope, schedule, and cost objectives into a
performance measurement baseline plan against which accomplishments may be
measured. Control Changes to the baseline.

IV.Use actual cost incurred and recorded in accomplishing the work performed.

V.Objectively assess accomplishments at the work performance level.

VI.Analyze significant variances from the plan, forecast impacts, and prepare an
estimate at completion based on performance to date and work to be performed.

VII.Use earned value information in the company’s management processes.

 

Elements of EVMS shall be applied to all Cost Plus Fixed Fee CLINs as part of
the Integrated Master Project Plan, the Contractor shall submit a written
summary of the management procedures that it will establish, maintain and use to
comply with EVMS requirements.

 

2.1.10Decision Gate Reporting: On completion of a stage of the product
development, as defined in the agreed upon Integrated Master Schedule and
Integrated Master Plan, the Contractor shall prepare and submit to the Project
Officer and the Contracting Officer a Decision Gate Report that contains (i)
sufficient detail, documentation and analysis to support successful completion
of the stage according to the predetermined qualitative and quantitative
criteria that were established for Go/No Go decision making; and (ii) a
description of the next stage of product development to be initiated and a
request for approval to proceed to the next stage of product development.

 

2.1.11Risk Management Plan: The Contractor shall develop a risk management plan
within 90 days of contract award highlighting potential problems and/or issues
that may arise during the life of the contract, their impact on cost, schedule
and performance, and appropriate remediation plans. This plan should reference
relevant WBS elements where appropriate. Updates to this plan shall be included
every three months (quarterly) in the monthly Project Status Report.

 

4

 

 

2.1.12Performance Measurement Baseline Review (PMBR): The Contractor shall
submit a plan for a PMBR to occur within 90 days of contract award. At the PMBR,
the Contractor and BARDA shall mutually agree upon the budget, schedule and
technical plan baselines (Performance Measurement Baseline). These baselines
shall be the basis for monitoring and reporting progress throughout the life of
the contract. The PMBR is conducted to achieve confidence that the baselines
accurately capture the entire technical scope of work, are consistent with
contract schedule requirements, are reasonably and logically planned, and have
adequate resources assigned. The goals of the PMBR are as FOLLOWS:

 

I.Jointly assess areas such as the Contractor’s planning for complete coverage
of the SOW, logical scheduling of the work activities, adequate resources, and
identification of inherent risks

II.Confirm the integrity of the Performance Measurement Baseline (PMB)

III.Foster the use of EVM as a means of communication

IV.Provide confidence in the validity of Contractor reporting

V.Identify risks associated with the PMB

VI.Present any revised PMBs for mutual agreement

VII.Present an Integrated Master Schedule: The Contractor shall deliver an
initial program level Integrated Master Schedule (IMS) that rolls up all
time-phased WBS elements down to the activity level. This IMS shall include the
dependencies that exist between tasks. This IMS will be agreed to and finalized
at the PMBR. DI-MGMT-81650 may be referenced as guidance in creation of the IMS
(see http://www.acq.osd.mil/pm/).

VIII.Present the Risk Management Plan

 

2.1.13Deviation Request: During the course of contract performance, in response
to a need to change IMS activities as baselined at the PMBR, the Contractor
shall submit a Deviation Report. This report shall request a change in the
agreed-upon IMS and timelines. This report shall include: (i) discussion of the
justification/rationale for the proposed change; (ii) options for addressing the
needed changes from the agreed upon timelines, including a cost-benefit analysis
of each option; and (iii) recommendations for the preferred option that includes
a full analysis and discussion of the effect of the change on the entire product
development program, timelines, and budget.

 

2.1.14Monthly and Annual Reports: The Contractor shall deliver Project Status
Reports on a monthly basis. The reports shall address the items below cross
referenced to the WBS, SOW, IMS, and EVM:

I.Executive summary highlighting the progress, issues, and relevant activities
in manufacturing, non-clinical, clinical, and regulatory;

II.Progress in meeting contract milestones, detailing the planned progress and
actual progress during the reporting period, explaining any differences between
the two and corrective steps;

 

5

 

 

III.Updated IMS;

IV.Updated EVM;

V.Updated Risk Management Plan (Every 3 months);

VI.Three month rolling forecast of planned activities;

VII.Progress of regulatory submissions;

VIII.Estimated and actual expenses;

 

2.1.15Data Management: The Contractor shall develop and implement data
management and quality control systems/procedures, including transmission,
storage, confidentiality, and retrieval of all contract data;

2.1.15.1Provide for the statistical design and analysis of data resulting from
the research;

2.1.15.2Provide raw data or specific analyses of data generated with contract
funding to the Project Officer, upon request.

 

2.2Non-Clinical Toxicology

2.2.1N/A (no scope)

 

2.3Non-Clinical

2.3.1Develop and validate […***…] to lower […***…].

2.3.2[…***…]: Conduct […***…] studies including […***…] studies, […***…], and
[…***…] studies in […***…].

2.3.3[…***…]

2.3.3.1Conduct […***…] study in […***…].

2.3.3.2Conduct […***…] studies including […***…] studies, […***…] studies
including […***…] for CMX-001 and […***…] in […***…].

2.3.4Use of […***…] as a CMX-001 Surrogate in […***…] Studies.

2.3.4.1Dose […***…] with […***…] to identify the concentration of the […***…] in
[…***…] associated with […***…] of […***…].

2.3.5Scaling of […***…] to […***…] by conducting studies with […***…] to
determine […***…] in […***…].

2.3.6[…***…] determination of CMX001, […***…] and […***…] in the […***…].

2.3.7Conduct […***…] experiments to demonstrate […***…] following effective
[…***…] prior to […***…].

2.3.8Conduct studies to optimize […***…] in […***…].

2.3.9Conduct CMX001 […***…] study in […***…] at a dose of CMX001 equivalent or
less than […***…] with treatment beginning at the […***…]

 

***Confidential Treatment Requested

 

6

 

 

2.4Clinical

2.4.1Measurement of […***…] levels in […***…] and correlate the […***…] levels
to studies conducted in […***…].

2.4.2Conduct expanded access protocol ([…***…]).

2.4.3Analyze data and provide a Final Report for […***…] evaluation of CMX001 in
patients ([…***…])

 

2.5Regulatory

2.5.1Engaging the FDA on a path to support the treatment of smallpox indication
with CMX-001

2.5.2Preparing materials for and requesting, scheduling and participating in all
meetings with the FDA, including meetings to review EUA and/or all other data
packages;

2.5.3Providing BARDA with (i) the initial draft minutes and final draft minutes
of any formal meeting with the FDA; (ii) final minutes of any informal meeting
with the FDA;

2.5.4Obtain FDA concurrence on the feasibility of the proposed […***…] with
CMX001/[…***…]/[…***…] in the […***…] ([…***…]), including FDA feedback on
[…***…] and review of data for the first […***…] enrolled in the […***…]
sub-study

2.5.5Develop and submit a revised […***…] for CMX001 for Treatment of Smallpox,
including […***…] for FDA review and comment, and revise the […***…] as
requested by FDA

 

2.6CMC

2.6.1Validation of the […***…] process: Validation of the process to demonstrate
the […***…] of a […***…] of acceptable quality will be performed.

2.6.2Validation of the […***…] process to produce […***…]: Validation of the
process to demonstrate the […***…] of a […***…] of acceptable quality will be
performed.

 

3.PHASE II: […***…]

 

Research and development of CMX001 for the treatment of smallpox to include the
following activities: […***…]. The contractor shall carry out the following
tasks and subtasks and in accordance with the agreed upon Integrated Master
Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall
further detail the conduct of the specific tasks and subtasks.

 

***Confidential Treatment Requested

 

7

 

 

3.1Program Management (consistent with section 2.1)

3.1.1Program management scope in BASE year is consistent with program management
scope in each option year.

 

3.2Non-Clinical toxicology

3.2.1N/A (no scope)

 

3.3Non-Clinical

3.3.1Quantify […***…] concentrations in […***…] from […***…].

3.3.2Determine […***…] for CMX001 in […***…] in […***…].

3.3.3Scaling of […***…] to […***…] - Review with BARDA and FDA the […***…]
generated to support scaling between […***…] and […***…] using […***…] as well
as comparisons of […***…] in the […***…].

3.3.4Determine […***…] for CMX001 in […***…] in […***…].

3.3.5Conduct […***…].

3.3.6Conduct […***…] and […***…]

3.3.7Chimerix will provide […***…] for the […***…] and […***…] conducted under
[…***…]

 

3.4Clinical

3.4.1N/A (No scope)

 

***Confidential Treatment Requested

 

8

 

 

3.5Regulatory

3.5.1Engaging the FDA on a path to support the treatment of smallpox indication
with CMX001

3.5.2Generating all necessary documentation for […***…]. [[…***…]]

3.5.3Preparing materials for and requesting, scheduling and participating in all
meetings with the FDA, including meetings to review EUA (if needed) and/or all
other data packages;

3.5.4Providing BARDA with (i) the initial draft minutes and final draft minutes
of any formal meeting with the FDA relating to the smallpox program; (ii) final
draft minutes of any informal meeting with the FDA relating to the smallpox
program.

 

3.6CMC

3.6.1N/A (No scope)

 

4.PHASE III: […***…]

 

Research and development of CMX001 for the treatment of smallpox and dsDNA
viruses to include the following activities: […***…] Study, […***…] Study,
[…***…]. The contractor shall carry out the following tasks and subtasks and in
accordance with agreed upon Integrated Master Schedule and Integrated Master
Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the
specific tasks and subtasks.

 

4.1Program Management (Consistent with section 2.1)

4.1.1Program management scope in BASE year is consistent with program management
scope in each option year.

 

4.2Non- Clinical toxicology

4.2.1N/A (no scope)

 

***Confidential Treatment Requested

 

9

 

 

4.3Non-Clinical

4.3.1[…***…] studies: A […***…] study will be conducted with the […***…] of
CMX001 selected based on the results of the […***…] and […***…] studies. […***…]
will be […***…] to receive […***…] beginning at the […***…] or the FDA agreed
upon trigger for treatment. The first […***…] study will be a […***…] study of
CMX001 in the […***…] model. A study will be conducted with an […***…] of CMX001
to determine the […***…] after observation of the FDA agreed upon trigger for
treatment. These studies will include […***…] and […***…]. The primary endpoint
will be […***…].

4.3.2[…***…] study of CMX001 in the […***…]: The […***…] study will compare
[…***…] with […***…] agreed upon with FDA. The studies will include […***…] and
[…***…] agreed upon with the FDA. The primary endpoint will be […***…].

4.3.3Conduct additional studies in […***…] to determine […***…] and […***…] for
CMX001 at […***…].

4.3.4Conduct […***…] of […***…].

 

4.4Clinical

4.4.1Clinical […***…] study to evaluate […***…] used in previous clinical
studies and […***…] developed for NDA. This study will […***…] to […***…] to
determine if […***…] are comparable.

 

4.5Regulatory

4.5.1Generating all necessary data and preparing documentation for an […***…]
meeting submissions to regulatory agencies;

4.5.2Preparing materials for and requesting, scheduling and participating in all
meetings with the FDA, including the […***…] Meeting, meetings to review
[…***…], EUA (if needed) and/or all other data packages;

4.5.3Providing BARDA with (i) the initial draft minutes and final draft minutes
of any formal meeting with the FDA relating to this Contract; (ii) final draft
minutes of any informal meeting with the FDA;

4.5.4Preparing an […***…] submission […***…].

 

***Confidential Treatment Requested

 

10

 

 

4.6CMC

4.6.1[…***…] in order to generate […***…] for registration and clinical trial
supplies.

 

5.PHASE IV: […***…]

 

Research and development of CMX-001 for the treatment of smallpox to include the
following activities: […***…], […***…] studies and phase I […***…] study. The
contractor shall carry out the following tasks and subtasks and in accordance
with agreed upon Integrated Master Schedule and Integrated Master Plan (defined
in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks
and subtasks.

 

5.1Program Management (Consistent with section 2.1)

5.1.1Program management scope in BASE year is consistent with program management
scope in each option year.

 

5.2Non-Clinical toxicology

5.2.1N/A (no scope)

 

5.3Non-Clinical

5.3.1[…***…] studies. […***…] will be randomized to receive […***…] beginning at
the […***…]. These studies will include […***…] and […***…] as well as […***…]
including […***…]. The primary endpoint will be […***…]

5.3.2[…***…] Studies. This study will determine the […***…] at the […***…].
[…***…] and […***…] at the […***…]. The primary endpoint will be […***…]. If FDA
requires a […***…] in the […***…] studies, the […***…] study may not be needed.

5.3.3Conduct […***…] Studies. This study will determine the […***…] at the
[…***…]. […***…] and […***…] at the […***…].

 

***Confidential Treatment Requested

 

11

 

 

5.4Clinical

5.4.1Phase 3 development including […***…] study, […***…] study, phase II
[…***…] study. A […***…] study will be conducted to compare the […***…] of
CMX001 in […***…] to […***…]. A […***…] study will be conducted to compare the
[…***…] of CMX001 when […***…]. A […***…] study will be conducted (if required)
to […***…] to support an NDA.

5.4.2Measurement of […***…] in […***…] and correlate the […***…] to studies
conducted in […***…] (if required).

5.4.3Compile […***…] for NDA submission. A […***…] collected from all CMX001
clinical studies, irrespective of indication, will be populated and analyzed in
order to support an NDA for smallpox.

 

5.5Regulatory

5.5.1Generating all necessary data and preparing documentation for NDA
submissions to regulatory agencies;

5.5.2Preparing materials for and requesting, scheduling and participating in all
meetings with the FDA, including meetings to review IND, EUA and/or all other
data packages;

5.5.3Providing BARDA with (i) the initial draft minutes and final draft minutes
of any formal meeting with the FDA; (ii) final draft minutes of any informal
meeting with the FDA

 

5.6CMC

5.6.1[…***…]. […***…] of the process to demonstrate the […***…] of a […***…]
will be performed.

 

6.PHASE V: […***…]

7.          

Research and development of CMX-001 for the treatment of smallpox to include the
following activities: […***…]. The contractor shall carry out the following
tasks and subtasks and in accordance with an agreed upon Integrated Master
Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall
further detail the conduct of the specific tasks and subtasks.

 

7.1Program Management (Consistent with section 2.1)

7.1.1Program management scope in BASE year is consistent with program management
scope in each option year.

 

***Confidential Treatment Requested

 

12

 

 

7.2Non-Clinical toxicology

7.2.1N/A (no scope)

 

7.3Non-Clinical

7.3.1[…***…] Studies. This study replicates […***…] if a larger sample size is
necessary to achieve a […***…] result.

 

7.4Clinical

7.4.1Compile […***…]. A database of […***…] data collected from all CMX001
clinical studies, irrespective of […***…], will be populated and analyzed in
order to support an NDA for smallpox.

 

7.5Regulatory

7.5.1Generating all necessary data and preparing documentation for NDA
submissions to regulatory agencies;

7.5.2Submitting NDA documentation to the FDA in a timely manner, consistent with
timelines set out in the contract and by the FDA.

7.5.3Preparing materials for and requesting, scheduling and participating in all
meetings with the FDA, including meetings to review IND, EUA and/or all other
data packages;

7.5.4Providing BARDA with (i) the initial draft minutes and final draft minutes
of any formal meeting with the FDA; (ii) final draft minutes of any informal
meeting with the FDA;

 

7.6CMC

7.6.1[…***…]. […***…] of the process to demonstrate the […***…] of a […***…]
will be performed.

 

8.Other Items

 

8.1Facilities, Equipment and Other Resources. (Contract: Section J)

The Contractor shall provide equipment; facilities and other resources required
for implementation of the SOW dated January 11, 2011[insert approval date] to
comply with all Federal and HHS regulations in:

 

***Confidential Treatment Requested

 

13

 

 

8.1.1The […***…] and use of […***…];

8.1.2The acquisition, handling, storage and shipment of […***…], including
[…***…] required for working with the […***…];

8.1.3The […***…] of […***…] under cGMP;

8.1.3.1The design and conduct of […***…]; and

8.1.3.2The conduct of […***…] studies to determine […***…] of […***…]

 

8.1.4Design and conduct of […***…] under GCP.

 

***Confidential Treatment Requested

 

14

 

 

REVISED MILESTONES ARTICLE F.2 DELIVERABLES   Current
Milestone #   Milestone Definition   Go Criteria   No-Go Criteria   Deliverable
  WBS/SOW #   Segment 1.   […***…]   […***…]   […***…]   […***…]   […***…]  
[…***…] 2.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…] 3.  
[…***…]   […***…]   […***…]   […***…]   […***…]   […***…] 4.   […***…]   […***…]
  […***…]   […***…]   […***…]   […***…] 5.   […***…]   […***…]   […***…]  
[…***…]   […***…]   […***…] 6.   […***…]   […***…]   […***…]   […***…]   […***…]
  […***…]

 

***Confidential Treatment Requested

 

 

 

 

7.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…] 8.   […***…]  
[…***…]   […***…]   […***…]   […***…]   […***…] 9.   No longer in development
plan.               N/A   N/A 10.   No longer in development plan.              
N/A   N/A 11.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…]

 

***Confidential Treatment Requested

 

 

 

 

12.   No longer in development plan.               N/A   N/A 13.   No longer in
development plan.               N/A   N/A 14.   […***…]   […***…]   […***…]  
[…***…]   […***…]   […***…] 15.   […***…]   […***…]   […***…]   […***…]  
[…***…]   […***…] 16.   […***…]   […***…]   […***…]   […***…]   […***…]  
[…***…] 17.   No longer in development plan.               N/A   N/A 18.  
[…***…]   […***…]   […***…]   […***…]   […***…]   […***…]

 

***Confidential Treatment Requested

 

 

 

 

19.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…] 20.   […***…]  
[…***…]   […***…]   […***…]   […***…]   […***…] 21.   […***…]   […***…]  
[…***…]   […***…]   […***…]   […***…] 22.   […***…]   […***…]   […***…]  
[…***…]   […***…]   […***…] 23.   […***…]   […***…]   […***…]   […***…]  
[…***…]   […***…] 24.   […***…]   […***…]   […***…]   […***…]   […***…]  
[…***…]

 

***Confidential Treatment Requested

 

 

 

 

25.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…] 26.   […***…]  
[…***…]   […***…]   […***…]   […***…]   […***…] BCA MILESTONE   […***…]  
[…***…]   […***…]   […***…]   […***…]   […***…] NEW OPTION 1 MILESTONE TO BE
ADDED TO ARTICLE F.2 DELIVERABLES OF THE CONTRACT 28.   […***…]   […***…]  
[…***…]   […***…]   […***…]   […***…]

 

***Confidential Treatment Requested

 

 

 

 

29.   […***…]   […***…]   […***…]   […***…]   […***…]   […***…]

 

***Confidential Treatment Requested